In addition, Cox’s proportional hazard analysis of UBE2O expression in patients with prostate cancer from Soonchunhyang University Hospital identified a correlation with between UBE2O immunohistochemical staining and the following (see Table 5, Table 6 and Table 7): clinical recurrence free (HR = 0.028[95% CI: 0.008–0.106], HR= 0.023[95% CI: 0.006–0.841], p < 0.001); Overall survival (HR = 0.503[95%CI: 0.197–1.289], HR = 0.310[95% CI: 0.112–0.856], p < 0.05). The gene discussed is UBE2O; the disease is prostate carcinoma.